Peer-reviewed journal articles

Annals of Internal Medicine

Out-of-Pocket Savings Among Medicare Part D Beneficiaries Under the Medicare Drug Price Negotiation Program

Castle G, Han J, Huskamp HA, Keating NL, Dusetzina SB.

• pharmacy benefit design
• pharmacoeconomics

Health Affairs Scholar

Using Prescription Drug Data for Timely Assessments of State Insurance Coverage Rates: A Validation Study

Rome BN, McIntyre A, Kim J, Han J, Kesselheim AS, Sommers BD.

• claim data analysis
• pharmacoepidemiology

JAMA

Medicare Spending Implications for Semaglutide under Voluntary Price Agreements

Dusetzina SB, Castle G, Han J, Leech AA, Zhu J.

• pharmacoeconomics
• pharmacy benefit design

Value in Health

Reanalyzing Value Assessments in American Heart Association Clinical Practice Guidelines Using Health Years in Total Instead of Quality-Adjusted Life-Years

Han J, Luviano A, Pandya A.

• health decision modeling
• cost-effectiveness analysis

Health Affairs

List Price Reductions among Brand-Name ICS-LABA Inhalers In 2024 Were Associated with Increased Generic Uptake

Han J, Wang SV, Kesselheim AS, Avorn J, Feldman WB.

• claim data analysis
• pharmacoepidemiology
• pharmacy benefit design

Health Affairs

Review Times for New Drugs and Submission Delays among the FDA and 4 International Regulators, 2014–22

Papanicolas I, Wouters OJ, Sawaya T, Han J, Wei J, Naci H.

• accelerated approval
• pharmacoeconomics
• rare disease treatment

JAMA Health Forum

Changes in Medication Use during Medicaid Continuous Enrollment and Unwinding

Rome BN, Han J, McIntyre A, Kesselheim AS, Sommers BD.

• claim data analysis
• pharmacoepidemiology

JAMA

Inhaler-related Greenhouse Gas Emissions in the US: A Serial Cross-sectional Analysis

Feldman WB, Han J, Raymakers AJN, Furie GL, Chesebro BB.

• pharmacoepidemiology

JNCI: Journal of the National Cancer Institute

Assessing Outcomes Emerging After Conversion to Regular Approval for Cancer Drug Indications Granted Accelerated Approval Drugs, 1992-2021

Tibau A, Romano A, Liu ITT, Han J, Cliff ERS, Kesselheim AS.

• accelerated approval
• pharmacoeconomics

Addiction Research & Theory

Public Discourse on Substance Use Behavior as a Driver of Public Policy: A Scoping Review of South Korean Academic and Official Literature

Sung M, Han J, Wade CG, Rees VW.

JAMA Dermatology

Use of and Cost of First-Line Biologic Medications to Treat Plaque Psoriasis in the US

Rome BN, Han J, Mooney H, Kesselheim AS.

• claim data analysis
• pharmacoepidemiology
• pharmacoeconomics

Health Affairs

First-in-Class Drugs Experienced Different Regulatory Treatment in the US and Europe

Han J, Kesselheim AS.

• first-in-class drug
• accelerated approval
• rare disease treatment
• pharmacoeconomics